A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells
expressing two synthetic constructs: first, a single-domain antibody that recognizes human
Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the
endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is
expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch
receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a
transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon
engagement with PD-L1 on cancer cells.